Integrated Chromosome 19 Transcriptomic and Proteomic Data Sets Derived from Glioma Cancer Stem-Cell Lines

One subproject within the global Chromosome 19 Consortium is to
define chromosome 19 gene and protein expression in glioma-derived
cancer stem cells (GSCs). Chromosome 19 is notoriously linked to glioma
by 1p/19q codeletions, and clinical tests are established to detect
that specific aberration. GSCs are tumor-initiating cells and are
hypothesized to provide a repository of cells in tumors that can self-replicate
and be refractory to radiation and chemotherapeutic agents developed
for the treatment of tumors. In this pilot study, we performed RNA-Seq,
label-free quantitative protein measurements in six GSC lines, and
targeted transcriptomic analysis using a chromosome 19-specific microarray
in an additional six GSC lines. The data have been deposited to
the ProteomeXchange with identifier PXD000563. Here we present insights
into differences in GSC gene and protein expression, including the
identification of proteins listed as having no or low evidence at
the protein level in the Human Protein Atlas, as correlated to chromosome
19 and GSC subtype. Furthermore, the upregulation of proteins downstream
of adenovirus-associated viral integration site 1 (AAVS1) in GSC11
in response to oncolytic adenovirus treatment was demonstrated. Taken
together, our results may indicate new roles for chromosome 19, beyond
the 1p/19q codeletion, in the future of personalized medicine for
glioma patients.

全球19号染色体联盟（Chromosome 19 Consortium）旗下的一项子项目，旨在明确胶质瘤来源癌症干细胞（glioma-derived cancer stem cells, GSCs）中19号染色体的基因与蛋白质表达谱。众所周知，1p/19q共缺失与胶质瘤存在密切关联，目前已建立临床检测方法以甄别该特异性染色体异常。GSCs作为肿瘤起始细胞，被认为是肿瘤中具备自我复制能力、且对现有肿瘤治疗用放疗及化疗药物产生耐药性的细胞储备库。在本预实验研究中，我们对6株GSCs开展了RNA测序（RNA-Seq）与无标记定量蛋白质组检测，并通过19号染色体特异性微阵列，对额外6株GSCs进行了靶向转录组分析。相关数据已以标识符PXD000563提交至ProteomeXchange数据库。本研究揭示了GSCs中基因与蛋白质表达的差异特征，包括鉴定出人类蛋白质图谱（Human Protein Atlas）中蛋白质水平证据匮乏或极低的蛋白质，这类蛋白质与19号染色体及GSCs亚型相关。此外，我们证实，在经溶瘤腺病毒处理的GSC11细胞中，腺相关病毒整合位点1（adenovirus-associated viral integration site 1, AAVS1）下游的蛋白质表达出现上调。综上，本研究结果表明，19号染色体在胶质瘤患者个性化医疗领域的潜在价值不止局限于1p/19q共缺失，可为未来相关研究提供全新视角。